article thumbnail

What the new private sale process regime means for private equity investors

JD Supra: Mergers

The UK Takeover Panel (the Panel) has published a new framework for private sale processes. If you are a private equity investor considering potential P2P acquisitions after receiving initial soundings from management teams, then this new regime should be helpful in enabling early stage talks to happen in private.

article thumbnail

Private Equity Profiles and Perspectives: An In-Depth Conversation with Pat Riley and Lukasz Wrona of Akoya Capital - Part 2

JD Supra: Mergers

To help businesses, investors, and deal professionals better understand the evolving private equity landscape in the lower middle market, Rob Connolly – a partner in and leader of LP’s Corporate Practice Group – shares a series of conversations with private equity firms and professionals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Institutional Investor Newsletter: 2024 End-of-Year Roundup

JD Supra: Mergers

A recent trend in continuation vehicles involves traditional private equity sponsors serving as the “lead investor” in lieu of, or in addition to, more traditional secondary buyers and institutional investors. By: DLA Piper

Investors 167
article thumbnail

California Governor Vetoes Bill Imposing New Requirements for Private Equity in Healthcare Transactions

JD Supra: Mergers

The Bill, if enacted, would have imposed new notice and consent requirements for private equity investors involved in healthcare transactions. On September 28, 2024, California Governor Gavin Newsom vetoed California Assembly Bill 3129 (the Bill). By: Robinson+Cole Health Law Diagnosis

article thumbnail

Trending Enforcement Targeting Private Equity Healthcare Portfolios Provides Important Compliance Reminder

JD Supra: Mergers

Over the last decade, private equity firms have acquired healthcare companies, hospitals, and clinics at an increasing rate. In fact, in those ten years, private equity firms have spent roughly $1 trillion on an estimated 8,000 healthcare deals. This trend is only expected to increase through 2024.

article thumbnail

Antitrust scrutiny of private equity deals intensifies

JD Supra: Mergers

Traditionally, private equity firms were seen as benign investors from an antitrust perspective. This is changing. In the past 12 months, PE-funded acquisitions have faced progressively more rigorous scrutiny by antitrust authorities. By: Allen & Overy LLP

article thumbnail

2024 Healthcare Private Equity Outlook & Trends

JD Supra: Mergers

As we begin 2024, we have highlighted the issues and trends that private equity (PE) investors should consider when evaluating transactions in the healthcare sector. W ith various headwinds resulting in down volume in 2023, buyers and sellers alike find themselves asking whether 2024 will see a rebound in deal activity.